abiraterone,olaparib
janssen,merck,astrazeneca
['biomarker', 'propel', 'olaparib', 'brca', 'marker ']
the awaited #propel biomarker analysis by esteemed #fredsaad rpfs of abi-olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit holds in intention to treat group. #esmo22 
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe